Hansen Disease among Micronesian and Marshallese Persons Living in
the United States by Woodall, Patricia et al.
An increasing proportion of Hansen disease cases 
in the United States occurs among migrants from the 
Micronesian region, where leprosy prevalence is high. We 
abstracted surveillance and clinical records of the National 
Hansen’s Disease Program to determine geographic, 
demographic, and clinical patterns. Since 2004, 13% of US 
cases have occurred in this migrant population. Although 
Hawaii reported the most cases, reports have increased in 
the central and southern states. Multibacillary disease in 
men predominates on the US mainland. Of 49 patients for 
whom clinical data were available, 37 (75%) had leprosy 
reaction, neuropathy, or other complications; 17 (37%) of 
46 completed treatment. Comparison of data from the US 
mainland with Hawaii and country of origin suggests under-
detection of cases in pediatric and female patients and with 
paucibacillary disease in the United States. Increased case 
ﬁ  nding and management, and avoidance of leprosy-labeled 
stigma, is needed for this population.
A
t 11 cases per 10,000 population and 8 per 10,000, 
respectively, in 2007, the small Paciﬁ  c Island nations 
of the Republic of the Marshall Islands and the Federated 
States of Micronesia have the highest prevalence of Hansen 
disease (HD), i.e., leprosy, in the world and have made 
little progress in the past decade toward the World Health 
Organization (WHO) leprosy elimination target of <1 per 
10,000 (1,2). During the ﬁ  rst quarter of 2010, 33 new cases 
were detected among the 54,000 residents of the Marshall 
Islands (3).
HD has been present in the United States for more than 
a century; the number of patients has remained relatively 
constant at 150–200 per year (4).The US National Hansen’s 
Disease Program (NHDP) has noted an increasing number 
of cases among US-resident Marshall Islanders and 
Micronesians, including several persons with advanced 
disease. In 1996, the Hawaii HD program reported a 
cluster involving 16 (5%) of 321 persons screened from 
a Marshallese migrant community (5,6). In 2002, the US 
Army noted 3 cases in 1 month in soldiers from this region 
(7). The recent reporting of multiple cases among the 
Marshallese community in northwestern Arkansas (Centers 
for Disease Control and Prevention, unpub. data, 2006) has 
drawn attention in a region unaccustomed to leprosy, with 
its stigmatizing historical connotations (8,9).
Under the terms of the Compacts of Free Association 
(the legal documents governing the relationships between 
the United States, Federated States of Micronesia, and the 
Republic of the Marshall Islands), citizens of this former US 
Trust Territory of the Paciﬁ  c Islands are not subject to usual 
immigration requirements but may freely enter, reside, and 
work in the United States for as long as they wish. They 
hold a unique legal status, are not classiﬁ  ed as immigrants, 
and maintain their country-of-origin citizenship. 
Transportation data indicate net emigration of an average 
of 952 Marshallese and 1,443 Micronesians annually, with 
a total of 38,325 emigrants for 1991–2006; almost all of 
these persons are thought to have immigrated to the United 
States and its territories (10). The actual distribution of this 
population within the United States is unknown; a speciﬁ  c 
category included in the 2010 US Census should provide 
this information. As economic and climatologic pressure 
drive increasing emigration from this HD-endemic former 
US Trust Territory, the US HD case load is expected to 
continue to increase, worsening health disparities and 
requiring increased program and local resources, although 
this increased case load is unlikely to create a public health 
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threat of transmission to the general population. Cultural 
and socioeconomic issues may affect case detection and 
long-term disease management in this population, including 
adherence to and completion of therapy.
The objective of this report is to describe, on the 
basis of secondary analysis of existing program data, the 
epidemiology of HD among Marshallese and Micronesian 
persons residing in the United States. The intent is to assist 
in providing resources to address a health disparity that 
disproportionately affects a group of a particular national 
origin, while at the same time avoiding worsening of ethnic 
and disease-related stigma. 
Materials and Methods
Demographic and disease-related data were abstracted 
for January 1990–October 2009 NHDP surveillance and 
clinical records of cases that identiﬁ  ed patients’ place of 
birth as the former Trust Territory (Marshall Islands or 
Micronesia). To facilitate global comparison, US cases 
(reported by using the Ridley-Jopling classiﬁ  cation system 
[11]) were reclassiﬁ   ed into the WHO multibacillary/
paucibacillary system (12). Country-of-origin HD data 
(case numbers or rates and age/sex/disease classiﬁ  cation) 
were abstracted from WHO reports (1,2,13). Country-of-
origin demographic data, US Census reports, and published 
reports relevant to migration patterns were abstracted to 
obtain denominator estimates where possible (14–17). Data 
were analyzed by using the SPSS version 16.0 statistical 
analysis program (SPSS Inc., Chicago, IL, USA). The 
study was approved by the Tulane University Institutional 
Review Board and exempted from review by the University 
of Arkansas for Health Sciences Institutional Review 
Board.
Results
The number of HD case-patients of Micronesian or 
Marshallese origin as a proportion of all US cases has risen 
over the past decade, with Micronesian and Marshallese 
patients constituting 90 (13%) of all 686 cases in the 
United States during 2004–2008 (Figure 1); the total source 
population of these 2 countries is only ≈170,000. Data are 
summarized in Table 1.
During January 2000–October 2009, 72 (55%) of US 
HD cases in Micronesian or Marshallese patients were 
reported in Hawaii. Of 29 Micronesian patients, 22 (76%) 
had multibacillary HD, 5 were female, and 3 were children. 
Of 43 Marshallese patients, 31 (72%) had multibacillary 
HD, 17 (17%) were female, and 1 was a child. Cases in 
Hawaii were not consistently reported to NHDP until the 
late 1990s; however, Bomgaars et al. reported that HD 
cases in 15 Micronesian and 23 Marshallese patients were 
noted there from 1990 through mid-1998, including the 
Marshallese cluster summarized in Table 2 (6).
Since 1990, 88 cases have been reported in 26 states 
of the US mainland (Figures 2, 3), 66 of these since 2000. 
Cases are increasingly being reported in inland locations. 
In all groups, the majority of patients were young men with 
multibacillary disease.
Among Micronesians, 55 cases occurred in 22 states 
of the US mainland (Table 1), 41 of these since 2000. 
All but 2 patients were <40 years of age, 42 (76%) had 
multibacillary disease, 10 (18%) were female, and 6 (10%) 
were children. Six patients reported having a previous 
HD diagnosis in the Federated States of Micronesia; 4 
of these patients reported having completed the WHO-
recommended 1 year of multidrug therapy (MDT) there. 
Of these patients, 14 (25%) originated in Chuuk State 
and 13 (24%) in Pohnpei State; for 28 (51%), the speciﬁ  c 
Federated State was not documented. During the 1990s, 11 
of 14 US-mainland HD cases were reported in the western 
coastal states of California, Washington, and Oregon. Since 
2000, a total of 28 of 41 cases were reported in midwestern 
and southern states (e.g., 6 in Iowa, 5 each in Texas and 
Florida, 3 in Missouri). Before moving to the reporting 
state, 21 patients had resided in other mainland states 
(often in multiple locations), 5 in Hawaii, and 8 in Guam. 
Of the 33 patients for whom clinical data were available, 
25 (76%) had >1 complication, including 15 patients with 
erythema nodosum leprosum (ENL) and 3 with severe 
facial involvement (lagophthalmos, blindness, nasopalatal 
destruction). One patient was pregnant when her HD 
was diagnosed. Of the 24 patients for whom pharmacy 
data were available (excluding 8 who had recently begun 
treatment), the complete US-recommended MDT course 
had been dispensed to 10 (42%) (Table 1).
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Figure 1. New patients of Marshallese or Micronesian origin with 
Hansen disease, compared with total new US patients with Hansen 
disease, 2000–2008. White bars, total US patients; black bars, total 
patients of Marshallese or Micronesian origin; red line, patients 
of Marshallese or Micronesian origin as percentage of total US 
patients.RESEARCH
Of the 33 US mainland Marshallese patients since 
1990 (25 of these since 2000), single cases were reported 
in 9 states, 2 in California, 5 in Washington, and 17 in 
Arkansas. All but 1 patient were <40 years of age, 25 (76%) 
had multibacillary disease, 11 (33%) were female, and 3 
(10%) were children. Three patients reported that their 
HD had been diagnosed in the Marshall Islands; none had 
completed MDT there. Nine patients had resided in other 
mainland states before moving to the reporting state; 5 had 
ﬁ  rst lived in Hawaii. Of the 16 patients for whom clinical 
data were available, 12 had >1 complication, including 
6 patients with ENL. Two patients were pregnant at the 
time of diagnosis. Of the 22 patients for whom pharmacy 
data were available (excluding 3 currently being treated), 
the complete US-recommended MDT course had been 
dispensed to 7 (32%) (Table 1).
Beginning in 1996, 17 HD cases have been reported 
among the ≈8,000–10,000 Marshallese living in 
northwestern Arkansas, 10 of these since 2004. All patients 
were <40 years of age, 15 (88%) had multibacillary disease, 
5 (30%) were female, and none were children. (Two 
25-year-old men with multibacillary disease, reported in 
November 2009 after completion of data collection for this 
study, are not included in this analysis.) Four patients had 
previously lived in other states, none in Hawaii. Speciﬁ  c 
island origin within the Marshall Islands was not reported; 
however, the general Arkansas Marshallese population is 
known to come from several different atolls. Of the 10 
patients for whom clinical data were available, 7 had >1 
complication, including 4 patients with ENL. Excluding 
the 2 patients currently being treated, the US-recommended 
MDT course had been dispensed to 3 (20%) (Table 1).
HD prevalence reported in the countries of origin is 
summarized in Figures 4 and 5. Because of the epidemiologic 
characteristics of HD (e.g., lack of biomarker, prolonged 
latency), surveillance is generally based on program 
records rather than population surveys; prevalence and 
case-detection rate (an approximation of incidence) are 
highly dependent on operational factors (Figure 5). Active 
case-detection programs were done in the Federated States 
of Micronesia in 1996 and 2005 and in the Marshall 
Islands in 1996 and 1998–1999 (18–20). Patterns of age/
sex/classiﬁ   cation distribution differed markedly during 
these years, with more children and paucibacillary disease 
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Table 2. Hansen disease patient data for multibacillary disease status, female sex, and age <15 y, as reported by sources other than 
the US National Hansen’s Disease Program* 
Data source Multibacillary disease, % Female sex, % Age <15 y
Federated States of Micronesia national data, 2000–2007† 44 35 34
Federated States of Micronesia Leprosy Elimination Campaign, 2005‡ 30 36 32
Republic of the Marshall Islands national data, 2000–2007† 55 42 23
Republic of the Marshall Islands Leprosy Elimination Campaign, 1999‡ 31 NA 35
Hawaii Marshallese cluster, 1998‡ 28 NA 39
*NA, data not available. 
†World Health Organization annual reports (national surveillance). 
‡Published reports from active case-finding campaigns (5,13,18–20).
Table 1. Hansen disease in residents of Micronesian and Marshallese origin, United States* 
Population group 
No. (%) patients  Median time from 
US entry to report, 
y (range) 
MDT,† 
no. (%) 
Complications, no. cases 
Total MB F
Age
<15 y  ENL RR 
Hand/foot
neuropathy Eye Other
Any 
(%)‡
Hawaii-residing 
Micronesians,
2000–2009§ 
29 22 (76)  5 (17)  3 (10)  1.5 (0–13)  NA NA NA NA NA NA NA
Hawaii-residing 
Marshallese, 
2000–2009§ 
43 31 (72)  17 (39)  1 (2)  1 (0–14)  NA NA NA NA NA NA NA
US Mainland 
Micronesians,
1990–2009 
55 42 (76)  10 (18)  6 (10)  3 (0–10)  10 (42)  15 3 8 6 3¶ 25
(77) 
US Mainland 
Marshallese, 
1990–2009 
33 25 (76)  11 (33)  3 (10)  2 (0–12)  7 (32)  6 3 5 1 1# 12
(75) 
Arkansas-residing
Marshallese, 
1990–2009 
17 15 (88)  5 (30)  0 (0)  2 (0–5)  3 (20)  4 2 2 0 0 12
(70) 
*Data from National Hansen’s Disease Program surveillance and clinical records, January 1990–October 2009. MB, multibacillary; MDT, multidrug 
therapy; ENL, erythema nodosum leprosum; RR, reversal reaction; NA, data not available. 
†MDT completed, excluding patients currently under active treatment. 
‡Patients for whom clinical data were available. 
§Pre-2000 data were not reported to National Hansen’s Disease Program. 
¶1 renal, 1 testicular, 1 palatal. 
#1 renal. Hansen Disease, United States
being identiﬁ  ed than during the usual passive surveillance 
years (Table 2); this pattern was also noted in the 1998 
Marshallese cluster in Hawaii.
Discussion
This study was descriptive; thus, comparisons among 
the various population subgroups are not statistically valid 
because of small numbers, varied data sources, and unknown 
age/sex distribution and denominators for the overall migrant 
populations. However, because age and sex distributions 
for the Arkansas, Hawaii, and Republic of the Marshall 
Islands Marshallese populations are similar (17), some 
crude comparisons can be made for these groups. Unless an 
unidentiﬁ  ed confounder is present, rates and distribution of 
cases would be expected to be similar in the 3 groups.
The Arkansas and Hawaii Marshallese populations 
were approximately the same size (3,000 each) and age/sex 
distribution (median age 20 years, M:F = 1) in 1998–2001; 
rough estimates place the current Arkansas population 
at 8,000–10,000 and Hawaii at 6,000–8,000. However, 
Hawaii has identiﬁ  ed 2.6× more cases since 2000, more 
female patients, and more paucibacillary disease and has 
found disease in children. Estimated case detection rates 
for Arkansas Marshallese persons are approximately half 
those for the Marshall Islands (Figure 6) and more skewed 
toward multibacillary disease, male, and adult patients 
(Table 1). This Arkansas and general US mainland pattern 
of predominantly multibacillary disease in men does not 
reﬂ   ect disease distribution patterns in the countries of 
origin or in Hawaii, suggesting under-detection of child, 
female, and paucibacillary disease patients rather than a 
biologic disease pattern (Tables 1, 2).
Of 49 mainland patients from both the Federated 
States of Micronesia and the Marshall Islands for whom 
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Figure 2. Hansen disease in patients of Marshallese or Micronesian 
origin, US mainland, by year reported, January 1990–October 
2009. 
Figure 3. States reporting 
Hansen disease in patients of 
Marshallese or Micronesian 
origin, US mainland, January 
1990–October 2009. The number 
of cases reported from each state 
is indicated. RESEARCH
clinical data were available, 37 (75%) had >1 complication, 
such as leprosy reaction, neuropathy, or other tissue 
involvement (e.g., palatal, renal, testicular). Although 
this ﬁ  nding could certainly reﬂ  ect reporting bias, with the 
most severely affected being more likely to seek care and 
to be reported, it does indicate the magnitude of the need 
for treatment resources for this population with limited 
health care access. The most severe cases of blindness 
and disﬁ  gurement occurred in Micronesians living alone 
or in very small ethnic communities, limiting the potential 
impact of ethnic-targeted services. The high number of 
ENL cases is of note because these patients may require 
corticosteroid treatment for many years. The low rates of 
MDT completion may contribute to poor clinical outcomes 
and possibly to drug resistance and ongoing transmission.
This study has several limitations. Hawaii did not 
report to the NHDP system until the late 1990s. Cases 
in Guam and Northern Marianas and among US military 
personnel are not reported to the NHDP. Reporting is not 
mandatory in all states but is likely to be fairly complete 
because of US physicians’ need for consultation on 
management of this unfamiliar condition. Since the 
2004 US Food and Drug Administration designation of 
clofazimine as an investigational drug, any patients with 
multibacillary disease are likely to have been reported so 
they would be able to receive the recommended MDT, 
although paucibacillary disease may be underreported. 
The increase in case reports since 2004 could reﬂ  ect this 
requirement.
Measures of adherence and completion of treatment, 
complications, and other clinical data were available only 
for mainland patients receiving direct or pharmacy care 
from the Baton Rouge NHDP facility. MDT is dispensed 
directly to active patients or provided to local physicians 
or health departments for supervision of treatment. 
Although adherence to and completion of treatment 
are monitored at national program level for HD patients 
attending clinics funded through contracts with the NHDP, 
for whom compliance exceeds 90% (D. Scollard, unpub. 
data), this level of follow-up has not been possible with 
private physicians, who are the providers for all of the 
Marshallese and Micronesian patients. In this situation, 
dispensing of MDT by the NHDP pharmacy was the only 
treatment measure available; actual adherence to treatment 
is unknown but is likely to be much lower and could be a 
subject for future study. A variety of cultural factors are 
likely to contribute to the low rate of treatment completion 
in this group, but evaluation of these cultural issues is 
beyond the scope of this study
Since achievement of the global leprosy elimination 
target of <1 case per 10,000 persons, attention has waned 
in some regions in which this neglected tropical disease 
persists. Although prevalence in the Republic of the 
Marshall Islands and the Federated States of Micronesia fell 
during the 1990s, rates have remained stable at high levels 
for the past decade. In these nonindustrialized nations, 
leprosy receives low priority in relation to more urgent 
public health concerns (rising rates of multidrug-resistant 
tuberculosis, 30% adult prevalence of type 2 diabetes, high 
infant mortality, and many others). Under the Compacts 
of Free Association, since the 1986 independence of the 
Federated States of Micronesia and the Republic of the 
Marshall Islands most health funding to these former 
territories  ﬂ   ows from the United States. Assistance 
with leprosy control in the countries of origin would, in 
addition to improving health conditions there, be the ﬁ  rst 
step toward preventing importation of cases to the United 
States. Because of the unique status of migrants from these 
nations to the United States, Micronesian and Marshallese 
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Figure 4. Hansen disease prevalence as cases per 10,000 
population, Federated States of Micronesia (FSM) and Republic of 
the Marshall Islands (RMI) 1991–2005 (1,2,13). 
Figure 5. Hansen disease cases per 100,000 population, Federated 
States of Micronesia (FSM) and Republic of the Marshall Islands 
(RMI) (1,2,13), 1990–2008. Hansen Disease, United States
migrants receive neither the health screening required for 
immigrants (which is not effective at preventing importation 
of HD because of its decades-long incubation period) nor 
targeted health services often available to large immigrant 
or refugee populations. Although legally residing in the 
United States, they remain citizens of their home nations 
and are thus ineligible for US health programs such as 
Medicare and Medicaid, although NHDP services such 
as biopsy interpretation, MDT, and direct outpatient care 
at the Baton Rouge facility are available. Many remain 
uninsured (>50% of the Arkansas Marshallese population) 
(17). Mainland state and local health departments are not 
typically resourced to serve either this population or this 
otherwise-rare condition. Hawaii receives more than $15 
million annually in Compact impact funds to partially 
address the multiple health issues of the Marshallese and 
Micronesian migrant populations, but these additional US 
funds have not been available to the mainland states. (21).
With the goal of decreasing health disparity and 
preventing disability, case-ﬁ  nding and case-management 
interventions are needed in US-resident Marshallese and 
Micronesian communities that are integrated into general 
health services and avoid the stigma of leprosy-labeled 
activities. Special efforts may be necessary to increase case 
detection among women and children. Large populations, 
such as the Arkansas Marshallese community, may be 
easier to reach with targeted but nonstigmatizing efforts, 
as has occurred in Hawaii. The small, widely distributed 
Micronesian communities, where the most severe, disabling 
cases have been identiﬁ  ed, may be more difﬁ  cult to reach.
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